The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Great post Bermuda and helps inform us all of possible way forward and once p1 is started we can firm up regulatory timetable once we know how much additional pre clinical work is required by Genmab.
The choice of specific product will depend on Genmab analysis of how quickly they feel they can progress development and their strategic plan- have not looked at their website for any clues.
Will be a good question at AGM as to the progress of other Glycans and the likelihood of further interest.
At current cash burn and know it will increase with bigger trials I still feel they have enough for another 2 years but of course they may announce something much earlier if other institutions want in although you would think taking out what Calculus may want to sell would be a good start.
Any new institutional buy in would have to be with RM and Vulpes support so I am very comfortable with any future raise as it will likely be for very good reasons and acceptable “ dilution” although I am hopeful they won’t need any and certainly more positive Modi news will transform landscape here
Morning Ray/TS,
The first deal is always the most difficult and it is a long time since SCLP cemented sone monetisation of any of its assets so very well done on Genmab deal which we mostly recognise as being an extremely good deal.
As Ray says this could easily become a virtual circle if that Science continues to be monetised.
There is no reason at all whilst the Genmab up front payment should not help pay for current or planned trials on other platforms as well as validate the other Glycans which can also do deals.
We know these milestone deals are usually backloaded and the real money involved does not come into play for 7 plus years as a minimum as a pre clinical asset.
Evening Drew it will likely take 8-10 years to commercialise product for SCLP to receive big milestone and royalties but there will milestone payments all way along.
So we know about upfront ,and we dint know about other deal inflection points but will be backloaded so positive p3 trials which will be 4-6 years and NDA submission and acceptance afterwards.
DG a very good post but you have to put it in perspective in rusk and time.
To achieve the $224m for any of the product deals you are looking at getting through all,the regulatory hurdles and that is fine as risk is with Genmab but if they don’t progress then SCLP don’t receive money.
Plus the first deal will take 8-10 years and the other 2 longer.
That is why imo the SP is where it is in ballpark terms.Yes it is under valued but a number of posters seem to be applying current valuations based on what they think the value will be when these products are Approved which is a long way ahead
Evening Chester,
Agree with you that the 1.35m was a buy even though at times in the first 45 minutes ( I was monitoring it non stop) the sell price was sometimes very slightly higher than the buy price.
I do believe the 1,5m was a sell but too close to call in reality but just seemed to change the direction once the action got close to 18p.
Morning absolutely great news.
As you say Bermuda the up front will be commercially sensitive but the other details of the deal confirm what a fantastic agreement this is and we can reasonably guess that the up front will be significant.
Morning absolutely great news.
As you say Bermuda the up front will be commercially sensitive but the other details of the deal confirm what a fantastic agreement this is and we can reasonably guess that the up front will be significant.
Morning WTP,
Both those bits of news are necessary due to regulatory reasons so not unexpected but as we all hope in the forward looking statements and Science update at AGM we may get an update.
Having attended a few AGMs what I have found is that the question session and afterwards are most useful bits.
I don’t find SCLP are especially good at communicating the latest info during presentations but they are pretty upfront in answering any questions,
So the info is there but often needs to be teased out by asking the right questions.
Evening and again agree Bermuda,
We must remember that however promising the science the only validation is data and then hopefully that data is positive enough to be endorsed further by a commercial deal to monetise the asset.
I constantly read on many pharma boards false assumptions like if it works in mice it must work in humans,if it shows great promise in p1 then it is destined to get Approval or if the Science is fantastic then it must succeed and many more.
Everyone’s opinions are valid but opinions without true validated evidence are purely that and you have to be very careful in extrapolating from there.
If you wish think of it in sporting terms you can have some of the best talent in your academy,, you can employ some of the best in the business with great resources but it does not guarantee success but yes helps reduce the risk.
Anyone who supported England during the coming if the Golden generation will understand the perspective.
Evening,
Just like old times with the Coggy show and a guest appearance from Zib who I thought would be hiding after yesterday ??